About Paul Lochhead, MBChB, PhD

Dr Paul Lochhead graduated in medicine from the University of Glasgow. He trained in internal medicine and gastroenterology in the United Kingdom before completing advanced clinical training in inflammatory bowel diseases at the Massachusetts General Hospital. Dr Lochhead is a member of the clinical team at the MGH Crohn’s and Colitis Center and holds a research appointment in the Clinical and Translational Epidemiology Unit. Dr Lochhead’s research focuses on using epidemiologic approaches to evaluate the role of environmental, medication and lifestyle factors in the pathogenesis of inflammatory bowel diseases and other gastrointestinal disorders.

Clinical Interests:



MGH Digestive Healthcare Center
165 Cambridge Street
9th floor
Boston, MA 02114-2782
Phone: 617-726-5560
Fax: 617-726-3080

Medical Education

  • PhD, University of Aberdeen School of Medicine
  • MBCHB, University of Glasgow
  • Residency, NHS Education for Scotland
  • Fellowship, Massachusetts General Hospital

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


  • View my most recent publications at PubMed

    Select Publications:

    • Nguyen LH, Lochhead P, Joshi AD, et al. No Significant Association Between Proton Pump Inhibitor Use and Risk of Stroke After Adjustment for Lifestyle Factors and Indication. Gastroenterology. 2018;154:1290-1297
    • Lochhead P, Hagan K, Joshi AD, et al. Association Between Proton Pump Inhibitor Use and Cognitive Function in Women. Gastroenterology. 2017;153:971-979
    •  Lochhead P, Khalili H, Ananthakrishnan AN, Richter JM, Chan AT. Association Between Circulating Levels of C-reactive Protein and Interleukin-6 and Risk of Inflammatory Bowel Disease.Clin Gastroenterol Hepatol. 2016 Jun;14:818-824
    • Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013;369:1095-105.
    • Lochhead P, Kuchiba A, Imamura Y, et al. Microsatellite instability and BRAFmutation testing in colorectal cancer prognostication.  J Natl Cancer Inst. 2013;105:1151-6.
    • Nishihara R, Lochhead P, Kuchiba A, et al.  Aspirin use and colorectal cancer incidence risk according to BRAFmutation status.  JAMA. 2013;309:2563-71.
    • Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367(17):1596-606.
    • Lochhead P, Frank B, Hold GL, et al. Association between a variation in the PSCAgene and upper gastrointestinal cancer in Caucasians. Gastroenterology 2011;140(2):435-41